Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 16/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554173 | 0.85 | ADORA1 (0.70) | ADORA1ADORA2ARPS6KA3GFERKMT2A | |
| SCHEMBL5447978 | 0.81 | ADORA1 (0.69) | ADORA1ADORA2ADHFRADORA2BGFER | |
| SCHEMBL5455467 | 0.80 | ADORA1 (0.64) | ADORA1ADORA2ARPS6KA3DHFRADORA2B | |
| SCHEMBL5459579 | 0.80 | ADORA1 (0.55) | ADORA1ADORA2ADHFRADORA2B | |
| SCHEMBL5460965 | 0.79 | ADORA1 (0.53) | ADORA1ADORA2ADHFRADORA2B | |
| Ammonia Solution, Strong SCHEMBL5454694 | 0.78 | ADORA1 (0.52) | ADORA1ADORA2ADHFRADORA2B | |
| SCHEMBL1554448 | 0.78 | ADORA1 (0.52) | ADORA1ADORA2ARPS6KA3ADORA2B | |
| SCHEMBL5451407 | 0.77 | ADORA1 (0.55) | ADORA1ADORA2ARPS6KA3 | |
| SCHEMBL1743003 | 0.76 | CYP2A6 (0.56) | — | |
| SCHEMBL1553929 | 0.76 | ADORA1 (0.61) | ADORA1ADORA2ARPS6KA3DHFRADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| CN-100519549-C | Pyrimidine compounds and pharmaceutical compositions containing the same | EISAI R&D MAN CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| CN-1575290-A | Pyrimidine derivatives and pharmaceutical compositions containing that compounds | EISAI CO LTD (JP) | 2005-02-02 | — | — | CN | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | ADORA1 328/4885ADORA2A 539/4885RPS6KA3 792/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | ADORA1 4/4885ADORA2A 2/4885RPS6KA3 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.